Ibrutinib-Venetoclax Produces High MRD-Negative Rates in CLL/SLL Ibrutinib-Venetoclax Produces High MRD-Negative Rates in CLL/SLL

A once-daily regimen of ibrutinib and venetoclax yielded molecular remissions in bone marrow and peripheral blood in a phase 2 trial.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news